Merit Medical Systems, Inc.
Merit Medical Systems, Inc. (MMSI) Financial Performance & Income Statement Overview
Review Merit Medical Systems, Inc. (MMSI) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Merit Medical Systems, Inc. (MMSI) Income Statement & Financial Overview
View the income breakdown for Merit Medical Systems, Inc. MMSI across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $355.35M | $355.16M | $339.85M | $337.58M |
| Cost of Revenue | $183.33M | $182.18M | $182.31M | $177.26M |
| Gross Profit | $172.02M | $172.98M | $157.53M | $160.32M |
| Gross Profit Ratio | $0.48 | $0.49 | $0.46 | $0.47 |
| R&D Expenses | $22.48M | $25.19M | $20.53M | $20.26M |
| SG&A Expenses | $107.49M | $111.07M | $99.64M | $94.58M |
| Operating Expenses | $130.99M | $136.42M | $120.27M | $114.85M |
| Total Costs & Expenses | $314.32M | $318.59M | $302.58M | $292.11M |
| Interest Income | $3.79M | $4.74M | $6.65M | $7.56M |
| Interest Expense | $6.57M | $7.99M | $7.50M | $7.68M |
| Depreciation & Amortization | $32.28M | $31.60M | $29.38M | $27.03M |
| EBITDA | $76.80M | $72.73M | $73.80M | $81.25M |
| EBITDA Ratio | $0.22 | $0.20 | $0.22 | $0.24 |
| Operating Income | $41.03M | $36.56M | $37.26M | $45.47M |
| Operating Income Ratio | $0.12 | $0.10 | $0.11 | $0.13 |
| Other Income/Expenses (Net) | -$3.08M | -$3.42M | -$604000.00 | -$103000.00 |
| Income Before Tax | $37.96M | $33.15M | $36.66M | $45.84M |
| Income Before Tax Ratio | $0.11 | $0.09 | $0.11 | $0.14 |
| Income Tax Expense | $7.81M | $5.20M | $8.21M | $10.12M |
| Net Income | $30.15M | $27.95M | $28.44M | $35.73M |
| Net Income Ratio | $0.08 | $0.08 | $0.08 | $0.11 |
| EPS | $0.51 | $0.48 | $0.49 | $0.61 |
| Diluted EPS | $0.49 | $0.46 | $0.48 | $0.61 |
| Weighted Avg Shares Outstanding | $58.90M | $58.54M | $58.23M | $58.14M |
| Weighted Avg Shares Outstanding (Diluted) | $61.28M | $60.61M | $59.54M | $58.74M |
The company's financials show resilient growth, with revenue advancing from $337.58M in Q2 2024 to $355.35M in Q1 2025. Gross profit remained healthy with margins at 48% in Q1 2025 compared to 47% in Q2 2024. Operating income hit $41.03M last quarter, sustaining a consistent 12% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $76.80M. Net income rose to $30.15M, while earnings per share reached $0.51. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan